STOCK TITAN

IRIX Form 4: CFO Romeo Dizon Adds 1,000 Shares to 49,745-Share Stake

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Iridex Corp Chief Financial Officer Romeo R. Dizon reported purchases of common stock on 08/26/2025. The filing shows two open-market buys: 750 shares at $1.26 and 250 shares at $1.25, for a total of 1,000 shares acquired. Following these transactions his beneficial ownership increased to 49,745 shares. The Form 4 was signed by an attorney-in-fact on 08/27/2025 and contains no derivative transactions or additional explanatory notes.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: CFO Romeo Dizon purchased 1,000 IRIX shares in two transactions, modestly increasing his stake to 49,745 shares.

These are straightforward, small open-market purchases reported on a Form 4. The transactions total 1,000 shares at prices of $1.26 and $1.25, respectively, and there are no reported derivative positions or dispositions. For investors, this filing is a routine insider purchase disclosure rather than a material corporate event. It provides transparency on insider activity but does not, by itself, change the companys financial condition or capital structure.

TL;DR: Insider buying by a named executive; procedural filing signed by attorney-in-fact.

The Form 4 is properly completed: it identifies the reporting person, relationship to the issuer (CFO and director), the transaction dates, purchase codes, share amounts, and post-transaction holdings. The signature is by attorney-in-fact, dated 08/27/2025. No amendments or additional disclosures are present. From a governance perspective, the filing meets disclosure obligations and signals routine insider accumulation without accompanying commentary or plans.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/26/2025 P 750 A $1.26 49,495 D
Common Stock 08/26/2025 P 250 A $1.25 49,745 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 08/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

19.60M
12.32M
27.64%
15.83%
1.6%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW